Noventure presents its pediatric range at the 51st ESPGHAN Annual Meeting in Geneva, 09-12 May 2018

As in previous years, Noventure has participated in the ESPGHAN Congress, held in Geneva, 09-12 May 2018.

Pediatric gastroenterologists are a key target group for the recommendation and endorsement of new approaches to GI conditions in children. 4.627 delegates from 100 countries participated at the congress, and many of them approached Noventure´s stand to request information.

Our innovative products intended for acute diarrhea (TASECTAN®, TASECTAN DUO® and XILAPLUS®) attracted a lot of interest from doctors.

Representatives from some of Noventure´s partners (this time Onco Kocsel and Angelini) joined our stand to meet and greet their own customers there with us.

TASECTAN®, TASECTAN DUO® and XILAPLUS® are Medical Devices and comply with the Essential Requirements of Directive 93/42/EEC and subsequent amendments.